BellaGel breast implant: 6-Year results of a prospective cohort study
- Author:
Joon Seok OH
1
;
Jae Hoon JEONG
;
Yujin MYUNG
;
Jeongseok OH
;
Shin Hyeok KANG
;
Eonju PARK
;
Ara KIM
;
Sa Ik BANG
;
Chan Yeong HEO
Author Information
- Publication Type:Original Article
- From:Archives of Plastic Surgery 2020;47(3):235-241
- CountryRepublic of Korea
-
Abstract:
Background:This is the first clinical study conducted among Asian women using breast implants manufactured by an Asian company. Four-year data regarding the safety and efficacy of BellaGel breast implants have already been published, and we now report 6-year data.
Methods:This study was designed to take place over 10 years. It included 103 patients who underwent breast reconstruction or augmentation using BellaGel breast implants. The rates of implant rupture and capsular contracture were measured and analyzed to evaluate the effectiveness of the breast implant.
Results:At patients’ 6-year postoperative visits, the implant rupture and capsular contracture rates were 1.15% and 2.30%, respectively. The implant rupture rate was 3.77% among reconstruction cases and 0% among augmentation cases. The capsular contracture rate was 5.66% among reconstruction cases and 0.83% among augmentation cases.
Conclusions:The 6-year data from this planned 10-year study suggest that the BellaGel cohesive silicone gel-filled breast implant is an effective and safe medical device that can be used in breast reconstruction and augmentation.
